Zepbound (Tirzepatide) Zepbound, another option for those in Bossier City, is a once-weekly GLP-1 and GIP agonist that has shown in trials to yield an average body weight reduction of 20.9% among participants
During the median follow-up period of 20 months (ranging from 6 to 48 months), the incidence of MACEs was significantly lower in the GLP-1RA group (7.63%)compared to the control group (19.85%) (HR 0.444
It is not medical advice, dosing guidance, usage instruction, or a recommendation
Using a fake version of any treatment removed all of the safety checks and clinical support that comes with a genuine prescription
2024 May 21
On the third, fourth, and fifth nights, half of the participants received DSIP intravenously, while the other half received a placebo